Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J Weisdorf, Daniel A Vallera, Jeffrey S Miller, Veronika Bachanova

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature CD19-expressing B lymphocytes and global dysfunction of immune effectors, including natural killer (NK) cells. CLL remains incurable, and novel approaches to refractory CLL are needed. Our group has previously described trispecific killer engager (TriKE) molecules that redirect NK cell function against tumor cells. TriKE reagents simultaneously bind an activating receptor on NK cells, CD16, and a tumor antigen while also providing an NK cell expansion signal via an interleukin-15 moiety. Here we developed the novel CD19-targeting 161519 TriKE. We demonstrate that 161519 TriKE induced killing of a CD19-expressing Burkitt’s lymphoma cell line and examined the impact on primary CLL targets using healthy donor and patient NK cells. 161519 TriKE induced potent healthy donor NK cell activation, proliferation, and directed killing. Furthermore, 161519 TriKE rescued the inflammatory function of NK cells obtained from CLL patient peripheral blood samples. Finally, we show that 161519 TriKE induced better directed killing of CLL in vitro when compared with rituximab. In conclusion, 161519 TriKE drives a potent activating and proliferative signal on NK cells, resulting in enhanced NK cell expansion and CLL target killing. Our findings indicate the potential immunotherapeutic value of 161519 TriKE in CLL.

Original languageEnglish (US)
Pages (from-to)897-907
Number of pages11
JournalBlood Advances
Volume3
Issue number6
DOIs
StatePublished - Mar 26 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Natural Killer Cells
Tissue Donors
Natural Killer Cell Receptors
Interleukin-15
Burkitt Lymphoma
Neoplasm Antigens
B-Lymphocytes
Cell Proliferation
Cell Line

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

Cite this

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. / Felices, Martin; Kodal, Behiye; Hinderlie, Peter; Kaminski, Michael F.; Cooley, Sarah; Weisdorf, Daniel J; Vallera, Daniel A; Miller, Jeffrey S; Bachanova, Veronika.

In: Blood Advances, Vol. 3, No. 6, 26.03.2019, p. 897-907.

Research output: Contribution to journalArticle

@article{6fcf6ae7cb9046b69ef86bbb0365f9c1,
title = "Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL",
abstract = "Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature CD19-expressing B lymphocytes and global dysfunction of immune effectors, including natural killer (NK) cells. CLL remains incurable, and novel approaches to refractory CLL are needed. Our group has previously described trispecific killer engager (TriKE) molecules that redirect NK cell function against tumor cells. TriKE reagents simultaneously bind an activating receptor on NK cells, CD16, and a tumor antigen while also providing an NK cell expansion signal via an interleukin-15 moiety. Here we developed the novel CD19-targeting 161519 TriKE. We demonstrate that 161519 TriKE induced killing of a CD19-expressing Burkitt’s lymphoma cell line and examined the impact on primary CLL targets using healthy donor and patient NK cells. 161519 TriKE induced potent healthy donor NK cell activation, proliferation, and directed killing. Furthermore, 161519 TriKE rescued the inflammatory function of NK cells obtained from CLL patient peripheral blood samples. Finally, we show that 161519 TriKE induced better directed killing of CLL in vitro when compared with rituximab. In conclusion, 161519 TriKE drives a potent activating and proliferative signal on NK cells, resulting in enhanced NK cell expansion and CLL target killing. Our findings indicate the potential immunotherapeutic value of 161519 TriKE in CLL.",
author = "Martin Felices and Behiye Kodal and Peter Hinderlie and Kaminski, {Michael F.} and Sarah Cooley and Weisdorf, {Daniel J} and Vallera, {Daniel A} and Miller, {Jeffrey S} and Veronika Bachanova",
year = "2019",
month = "3",
day = "26",
doi = "10.1182/bloodadvances.2018029371",
language = "English (US)",
volume = "3",
pages = "897--907",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

AU - Felices, Martin

AU - Kodal, Behiye

AU - Hinderlie, Peter

AU - Kaminski, Michael F.

AU - Cooley, Sarah

AU - Weisdorf, Daniel J

AU - Vallera, Daniel A

AU - Miller, Jeffrey S

AU - Bachanova, Veronika

PY - 2019/3/26

Y1 - 2019/3/26

N2 - Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature CD19-expressing B lymphocytes and global dysfunction of immune effectors, including natural killer (NK) cells. CLL remains incurable, and novel approaches to refractory CLL are needed. Our group has previously described trispecific killer engager (TriKE) molecules that redirect NK cell function against tumor cells. TriKE reagents simultaneously bind an activating receptor on NK cells, CD16, and a tumor antigen while also providing an NK cell expansion signal via an interleukin-15 moiety. Here we developed the novel CD19-targeting 161519 TriKE. We demonstrate that 161519 TriKE induced killing of a CD19-expressing Burkitt’s lymphoma cell line and examined the impact on primary CLL targets using healthy donor and patient NK cells. 161519 TriKE induced potent healthy donor NK cell activation, proliferation, and directed killing. Furthermore, 161519 TriKE rescued the inflammatory function of NK cells obtained from CLL patient peripheral blood samples. Finally, we show that 161519 TriKE induced better directed killing of CLL in vitro when compared with rituximab. In conclusion, 161519 TriKE drives a potent activating and proliferative signal on NK cells, resulting in enhanced NK cell expansion and CLL target killing. Our findings indicate the potential immunotherapeutic value of 161519 TriKE in CLL.

AB - Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature CD19-expressing B lymphocytes and global dysfunction of immune effectors, including natural killer (NK) cells. CLL remains incurable, and novel approaches to refractory CLL are needed. Our group has previously described trispecific killer engager (TriKE) molecules that redirect NK cell function against tumor cells. TriKE reagents simultaneously bind an activating receptor on NK cells, CD16, and a tumor antigen while also providing an NK cell expansion signal via an interleukin-15 moiety. Here we developed the novel CD19-targeting 161519 TriKE. We demonstrate that 161519 TriKE induced killing of a CD19-expressing Burkitt’s lymphoma cell line and examined the impact on primary CLL targets using healthy donor and patient NK cells. 161519 TriKE induced potent healthy donor NK cell activation, proliferation, and directed killing. Furthermore, 161519 TriKE rescued the inflammatory function of NK cells obtained from CLL patient peripheral blood samples. Finally, we show that 161519 TriKE induced better directed killing of CLL in vitro when compared with rituximab. In conclusion, 161519 TriKE drives a potent activating and proliferative signal on NK cells, resulting in enhanced NK cell expansion and CLL target killing. Our findings indicate the potential immunotherapeutic value of 161519 TriKE in CLL.

UR - http://www.scopus.com/inward/record.url?scp=85068307630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068307630&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018029371

DO - 10.1182/bloodadvances.2018029371

M3 - Article

C2 - 30890546

AN - SCOPUS:85068307630

VL - 3

SP - 897

EP - 907

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 6

ER -